A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

This study is looking at a new medicine called efruxifermin (EFX) for people with a liver condition called compensated cirrhosis due to NASH/MASH. Compensated cirrhosis is when the liver is scarred but still working well. NASH (Non-Alcoholic SteatoHepatitis) and MASH (Metabolic Associated SteatoHepatitis) are liver diseases caused by fat buildup, leading to inflammation and scarring. This study is randomized, double-blind, and placebo-controlled, meaning patients are randomly chosen to get either the medicine or a fake treatment (placebo) without knowing which one they receive.

• The study will happen in multiple centers, meaning you might have to visit the clinic several times.
• Only people with proven compensated cirrhosis due to NASH/MASH can join.
• People with other liver diseases or certain diabetes conditions cannot participate.

If you meet the criteria and are interested, you could be helping find a new treatment for NASH/MASH-related cirrhosis. There might be risks or side effects, so it’s important to talk to your doctor.